
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries
Sr. Associate – Value & Access
At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to our communities through philanthropy and volunteerism. We give our best effort to our work, and we put people first. We’re looking for people who are determined to make life better for people around the world.
The primary purpose of this role is to assist in securing market access via demonstrating the value of Lilly products through the product reimbursement life cycle. Sr. Associate-Value & Access is responsible for implementing the strategic plan for access, developing best-in-class dossiers for submissions and/or re-submissions to government. The Sr. Associate-Value & Access owns the value proposition/payer value message of Lilly products and delivers to payers throughout the product lifecycle. The Sr. Associate-Value & Access is also responsible for HEOR planning & implementation evaluating HO data in consultation with regional VEOHO team to tailor quality pharmaco-economic model on time and on budget to support the reimbursement of the products across the Lilly portfolio.
Lilly is dedicated to helping individuals with disabilities to actively engage in the workforce, ensuring equal opportunities when vying for positions. If you require accommodation to submit a resume for a position at Lilly, please complete the accommodation request form (https://careers.lilly.com/us/en/workplace-accommodation) for further assistance. Please note this is for individuals to request an accommodation as part of the application process and any other correspondence will not receive a response.
Lilly does not discriminate on the basis of age, race, color, religion, gender, sexual orientation, gender identity, gender expression, national origin, protected veteran status, disability or any other legally protected status.
#We Are Lilly
閲覧数
0
応募クリック
0
Mock Apply
0
スクラ ップ
0
類似の求人

Sr Program Administrator
Honeywell · Korea, Republic of, KR

Senior Consultant - Tech Consulting - FS - CNS - TC - Enterprise Technology Strategy - Mumbai
EY

Solution Engineering: Graduates Internship Opportunities
Microsoft · Korea, Seoul, Seoul

Support Escalation Manager
Microsoft · Korea, Seoul, Seoul

Procurement Planner Sr / AFSOC ACTS Program
Lockheed Martin · Kirtland AFB, New Mexico
Eli Lillyについて

Eli Lilly
PublicEli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
10,001+
従業員数
Korea
本社所在地
$588B
企業価値
レビュー
10件のレビュー
3.8
10件のレビュー
ワークライフバランス
3.2
報酬
4.1
企業文化
3.7
キャリア
2.8
経営陣
3.9
72%
知人への推奨率
良い点
Excellent compensation and benefits
Supportive management and leadership
Flexible work arrangements
改善点
Limited career advancement opportunities
High stress and demanding workload
Fast-paced and high-pressure environment
給与レンジ
56件のデータ
Mid/L4
Senior/L5
Mid/L4 · ADVISOR - BRD ANALYTICAL DEVELOPMENT
2件のレポート
$188,000
年収総額
基本給
$145,411
ストック
-
ボーナス
-
$188,000
$188,000
面接レビュー
レビュー2件
難易度
2.5
/ 5
期間
14-28週間
内定率
100%
体験
ポジティブ 50%
普通 50%
ネガティブ 0%
面接プロセス
1
Application Review
2
HR Screen
3
Phone/Video Interview
4
Hiring Manager Interview
5
Final Interview/Panel
6
Offer
よくある質問
Behavioral/STAR
Past Experience
Culture Fit
Industry Knowledge
Technical Knowledge
最新情報
Eli Lilly: A Heavyweight Battle Isn't Won In Round 1 (NYSE:LLY) - Seeking Alpha
Seeking Alpha
News
·
1w ago
Why Eli Lilly (LLY) Shares Are Trading Lower Today - StockStory
StockStory
News
·
1w ago
A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B - statnews.com
statnews.com
News
·
1w ago
Lilly's obesity pill records modest second week as battle with Novo intensifies - Reuters
Reuters
News
·
1w ago